Citigroup

Shares of Intercept Pharmaceuticals Inc (NASDAQ: ICPT), which is considered the frontrunner in the race for a non-alcoholic steatohepatitis, or NASH, drug, are fairly valued at current levels, according to an analyst at Citigroup. The Analyst Joel Beatty downgraded Intercept from Buy to Neutral and...

Uber Technologies Inc (NYSE: UBER) shares are down about 28% since the ride-hailing service's IPO, and Lyft Inc (NASDAQ: LYFT) shares are down about 39%.  What's In Store For Uber In 2020?  Multiple analysts are maintaining bullish ratings on Uber despite the stock's...

Galera Therapeutics Inc (NASDAQ: GRTX), a biopharma company working on novel therapeutics for transforming radiotherapy treatment in cancer, recently IPO'd, offering 5 million shares at $12 apiece. Following the expiry of the IPO quiet period, Citigroup analyst Yigal Nochomovitz initiated...

Citi upgraded Altria Group Inc. (NYSE: MO) as part of a more bullish general outlook on tobacco companies, but dropped its rating on Philip Morris International Inc. (NYSE: PM). The stocks moved in accordance, with Altria shares up and Philip Morris stock dropping. The Analyst Citi’s Adam...

Arista Networks Inc (NYSE: ANET) shares were plunging to a two-year low after the maker of data center switches issued a downbeat fourth-quarter outlook Thursday.  The Analysts MKM Partners analyst Michael Genovese maintained a Neutral rating on Arista and lowered the fair value estimate...

Investment bank Citigroup has promoted Jane Fraser as the corporation’s president, its CEO Michael Corbat announced on Thursday. The position, which had been vacant since April after the retirement of company stalwart Jame Forese, is usually understood to be reserved for the next-in-line CEO...

Citigroup upgraded Uber Technologies Inc (NYSE: UBER) Monday, citing the potential for the stock to rise on better third quarter earnings. The Analyst Itay Michaeli upgraded Uber from Neutral to Buy and maintained a $45 price target. The Thesis Second-half revenue for the ridesharing pioneer is...

AbbVie Inc (NYSE: ABBV) shares are advancing to their highest level since early July following a positive analyst action on the stock. The Analyst Citigroup analyst Andrew Baum upgraded shares of AbbVie from Neutral to Buy with a $90 price target, suggesting roughly 25% upside from current...

Sell-side analysts said Tuesday that much of what activist investor Elliott Management is suggesting for AT&T Inc. (NYSE: T) is already being contemplated — but public criticism from the new investor might make the company more aggressive and forthcoming about its plans....

Following the near 100% rally in shares of Solid Biosciences Inc (NASDAQ: SLDB) in August, one Citigroup analyst said the stock price is diverging from worsening fundamentals. The Analyst Joel Beatty downgraded Solid Biosciences from Neutral to Sell and maintained a $6 price target. The...

U.S. banks aim to leverage fintech in the payments, financial markets, data and blockchain spaces. “In 2019 YTD, U.S. banks have participated in 24 equity deals to fintech companies. This follows a record 2018, where U.S. banks backed 45 equity deals to fintech startups -- a 180% increase...

Juniper Networks, Inc. (NYSE: JNPR) shares are down 5.6% in the past year, but at least one large option trader is betting Juniper’s earnings report expected out later this month won’t save the slumping stock. The Trade On Monday morning, Benzinga Pro subscribers received an option...

Mirati Therapeutics Inc (NASDAQ: MRTX)'s shares have been on a tear, advancing over 50 percent since Amgen, Inc. (NASDAQ: AMGN) uploaded an online abstract of its non-small cell lung cancer candidate May 15 to be presented at the ASCO 2019 annual meeting. An analyst at...

The highly volatile biotech stocks present a high-risk-high-reward proposition. Judicious stock picking is essential to ride the superlative rally in some of these stocks in the wake of make-or-break binary events. Here's a brief on a few small-cap biotech stocks Citigroup analyst Yigal...

Data analytics company Splunk Inc (NASDAQ: SPLK) reported a beat-and-raise first quarter Thursday. Notwithstanding the solid results, the stock was sharply lower in Friday's session. BTIG analyst Edward Parker told Benzinga Friday that Spunk had a "great quarter," but billings...